Advertisement

Collaboration › Details
BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023
![]() |
Period | 2023-01-10 |
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Partner, 1st | BioNTech SE (Nasdaq: BNTX) |
Group | BioNTech (Group) | |
Partner, 2nd | J.P. Morgan Securities LLC | |
![]() |
Product | J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco |
Product 2 | mRNA technology | |
![]() |
Person | Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH) |
Person 2 | Maas, Sylke (BioNTech 202005 VP Investor Relations + Business Strategy) | |
BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz.
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.
A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.com.
CONTACT
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Record changed: 2023-01-05 |
Advertisement

More documents for BioNTech (Group)
- [1] BioNTech SE. (8/17/23). "Press Release: BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer". Tübingen & Boston, MA....
- [2] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
- [3] Biotheus Inc.. (7/19/23). "Press Release: Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech". Zhuhai....
- [4] Zhejiang Doer Biologics Co., Ltd.. (7/10/23). "Press Release: Doer Biologics Announces License Agreement with BioNTech". Hangzhou....
- [5] BioNTech SE. (6/29/23). "Press Release: BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC". Mainz & Rockville, MD....
- [6] BioNTech AG. (3/20/23). "Press Release: BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications". Mainz & Rockville, MD....
- [7] BioNTech AG. (3/14/23). "Press Release: Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years". New York & Mainz....
- [8] BioNTech AG. (3/13/23). "Press Release: Update on First BioNTainer for African-based mRNA Manufacturing Facility". Mainz & Kigali....
- [9] BioNTech AG. (3/1/23). "Press Release: BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel". Jerusalem....
- [10] BioNTech SE. (2/10/23). "Press Release: Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program". New York, NY & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top